Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enochian Biosciences Inc.

0.7000
0.0000
Volume:- -
Turnover:64.17K
Market Cap:42.52M
PE:-0.36
High:0.7000
Open:0.7000
Low:0.7000
Close:0.7000
52wk High:2.99
52wk Low:0.3928
Shares:60.74M
Float Shares:28.98M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9447
EPS(LYR):-2.1595
ROE:-93.88%
ROA:-9.94%
PB:0.64
PE(LYR):-0.32

Loading ...

Company Profile

Company Name:
Enochian Biosciences Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.